Nature Reviews Urology最新文献_第6页

PIONEER big data platform for prostate cancer: lessons for advancing future real-world evidence research 前列腺癌 PIONEER 大数据平台：推进未来真实世界证据研究的经验教训

IF 15.3 1区医学

Nature Reviews Urology Pub Date : 2024-09-09 DOI: 10.1038/s41585-024-00925-4

Ailbhe Lawlor, Katharina Beyer, Beth Russell, Carl Steinbeisser, Anders Bjartell, Bertrand De Meulder, Muhammad Imran Omar, Tim Hulsen, John Butler, James N’Dow, Juan Gómez Rivas, Giorgio Gandaglia, Rossella Nicoletti, Vasileios Sakalis, Emma Jane Smith, Monika Maass, Jihong Zong, Louise Fullwood, Thomas Abbott, Azadeh Tafreshiha, Kishore Papineni, Robert Snijder, Denis Horgan, Sarah Seager, Susan Evans-Axelsson, Maria J. Ribal, Monique J. Roobol, Mieke Van Hemelrijck

{"title":"PIONEER big data platform for prostate cancer: lessons for advancing future real-world evidence research","authors":"Ailbhe Lawlor, Katharina Beyer, Beth Russell, Carl Steinbeisser, Anders Bjartell, Bertrand De Meulder, Muhammad Imran Omar, Tim Hulsen, John Butler, James N’Dow, Juan Gómez Rivas, Giorgio Gandaglia, Rossella Nicoletti, Vasileios Sakalis, Emma Jane Smith, Monika Maass, Jihong Zong, Louise Fullwood, Thomas Abbott, Azadeh Tafreshiha, Kishore Papineni, Robert Snijder, Denis Horgan, Sarah Seager, Susan Evans-Axelsson, Maria J. Ribal, Monique J. Roobol, Mieke Van Hemelrijck","doi":"10.1038/s41585-024-00925-4","DOIUrl":"https://doi.org/10.1038/s41585-024-00925-4","url":null,"abstract":"Prostate Cancer Diagnosis and Treatment Enhancement through the Power of Big Data in Europe (PIONEER) is a European network of excellence for big data in prostate cancer. PIONEER brings together 34 private and public stakeholders from 9 countries in one multidisciplinary research consortium with the aim of positively transforming the field of prostate cancer clinical care by answering pressing questions related to prostate cancer screening, diagnosis and treatment. PIONEER has developed a unique state-of-the-art big data analytic platform by integrating existing data sources from patients with prostate cancer. PIONEER leveraged this platform to address prioritized research questions, filling knowledge gaps in the characterization, management and core outcomes of prostate cancer across the different disease stages. The network has benefited from sustained patient and stakeholder involvement and engagement, but many challenges remain when using real-world data for big data projects. To continue to advance prostate cancer care, data need to be available, suitable methodologies should be selected and mechanisms for knowledge sharing must be in place. Now acting as the prostate cancer arm of the European Association of Urology’s new endeavour, UroEvidenceHub, PIONEER maintains its goal of maximizing the potential of big data to improve prostate cancer care.","PeriodicalId":19088,"journal":{"name":"Nature Reviews Urology","volume":"72 1","pages":""},"PeriodicalIF":15.3,"publicationDate":"2024-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142158995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Non-coding transcriptome profiles in clear-cell renal cell carcinoma 透明细胞肾细胞癌的非编码转录组图谱

IF 15.3 1区医学

Nature Reviews Urology Pub Date : 2024-09-06 DOI: 10.1038/s41585-024-00926-3

Tereza Tesarova, Ondrej Fiala, Milan Hora, Radka Vaclavikova

{"title":"Non-coding transcriptome profiles in clear-cell renal cell carcinoma","authors":"Tereza Tesarova, Ondrej Fiala, Milan Hora, Radka Vaclavikova","doi":"10.1038/s41585-024-00926-3","DOIUrl":"https://doi.org/10.1038/s41585-024-00926-3","url":null,"abstract":"Clear-cell renal cell carcinoma (ccRCC) is a common urological malignancy with an increasing incidence. The development of molecular biomarkers that can predict the response to treatment and guide personalized therapy selection would substantially improve patient outcomes. Dysregulation of non-coding RNA (ncRNA) has been shown to have a role in the pathogenesis of ccRCC. Thus, an increasing number of studies are being carried out with a focus on the identification of ncRNA biomarkers in ccRCC tissue samples and the connection of these markers with patients’ prognosis, pathological stage and grade (including metastatic potential), and therapy outcome. RNA sequencing analysis led to the identification of several ncRNA biomarkers that are dysregulated in ccRCC and might have a role in ccRCC development. These ncRNAs have the potential to be prognostic and predictive biomarkers for ccRCC, with prospective applications in personalized treatment selection. Research on ncRNA biomarkers in ccRCC is advancing, but clinical implementation remains preliminary owing to challenges in validation, standardization and reproducibility. Comprehensive studies and integration of ncRNAs into clinical trials are essential to accelerate the clinical use of these biomarkers.","PeriodicalId":19088,"journal":{"name":"Nature Reviews Urology","volume":"1 1","pages":""},"PeriodicalIF":15.3,"publicationDate":"2024-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142142610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Artificial intelligence in the management of prostate cancer. 人工智能在前列腺癌治疗中的应用。

IF 12.1 1区医学

Nature Reviews Urology Pub Date : 2024-09-04 DOI: 10.1038/s41585-024-00938-z

Raghav Khanna, Alejandro Granados Martinez, Nicholas Raison, Sebastien Ourselin, Alberto Briganti, Francesco Montorsi, Prokar Dasgupta

引用次数: 0

Videourodynamics — role, benefits and optimal practice Videourodynamics - 作用、益处和最佳实践

IF 15.3 1区医学

Nature Reviews Urology Pub Date : 2024-08-29 DOI: 10.1038/s41585-024-00923-6

Mikolaj Przydacz, Howard B. Goldman

{"title":"Videourodynamics — role, benefits and optimal practice","authors":"Mikolaj Przydacz, Howard B. Goldman","doi":"10.1038/s41585-024-00923-6","DOIUrl":"https://doi.org/10.1038/s41585-024-00923-6","url":null,"abstract":"Videourodynamics (VUDS) is an advanced diagnostic procedure that simultaneously combines functional and anatomical evaluation of the lower urinary tract. The goal of this synchronous assessment is to promote accurate diagnosis of the aetiology responsible for patient symptoms, improving therapeutic decision-making. Overall, high-quality VUDS is advocated when other tests such as traditional urodynamics might not provide sufficient data to guide therapy, particularly in patients with complex, persistent or recurrent dysfunctions of the lower urinary tract. Additionally, VUDS is often crucial in the follow-up monitoring of many patients with these dysfunctions. A VUDS study is frequently considered a gold standard in patients with neurogenic lower urinary tract dysfunction, female bladder outlet obstruction or congenital anomalies of the lower urinary tract. Nevertheless, this specialized test should be limited to patients in whom VUDS data add value. Particularly, reliable studies comparing the effect of diagnosis with and without imaging on management outcomes are lacking, and no standardized procedures for undertaking VUDS are available. Additionally, patients should be carefully selected for VUDS evaluation, considering the increased cost and risks associated with radiological imaging. In routine practice, clinicians should balance the additional value of synchronous imaging and the enhanced diagnostic precision of VUDS against the limitations of this approach, which mainly include an uncertain effect of VUDS on final treatment outcomes.","PeriodicalId":19088,"journal":{"name":"Nature Reviews Urology","volume":"379 1","pages":""},"PeriodicalIF":15.3,"publicationDate":"2024-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142090189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Quest for a genetic biomarker for sickle cell disease priapism: rationale, progress and implications. 寻找镰状细胞病早衰的基因生物标志物：原理、进展和影响。

IF 12.1 1区医学

Nature Reviews Urology Pub Date : 2024-08-27 DOI: 10.1038/s41585-024-00927-2

Oluwafolajimi Adesanya, Arthur L Burnett

引用次数: 0

The interplay between male fertility, mental health and sexual function. 男性生育能力、心理健康和性功能之间的相互作用。

IF 12.1 1区医学

Nature Reviews Urology Pub Date : 2024-08-27 DOI: 10.1038/s41585-024-00936-1

Vincent J Straub, Melinda C Mills

引用次数: 0

Immune effects of α and β radionuclides in metastatic prostate cancer α和β放射性核素对转移性前列腺癌的免疫效应

IF 12.1 1区医学

Nature Reviews Urology Pub Date : 2024-08-27 DOI: 10.1038/s41585-024-00924-5

Sapna Lunj, Tim Andrew Davies Smith, Kimberley Jayne Reeves, Fred Currell, Jamie Honeychurch, Peter Hoskin, Ananya Choudhury

{"title":"Immune effects of α and β radionuclides in metastatic prostate cancer","authors":"Sapna Lunj, Tim Andrew Davies Smith, Kimberley Jayne Reeves, Fred Currell, Jamie Honeychurch, Peter Hoskin, Ananya Choudhury","doi":"10.1038/s41585-024-00924-5","DOIUrl":"10.1038/s41585-024-00924-5","url":null,"abstract":"External beam radiotherapy is used for radical treatment of organ-confined prostate cancer and to treat lesions in metastatic disease whereas molecular radiotherapy with labelled prostate-specific membrane antigen ligands and radium-223 (223Ra) is indicated for metastatic prostate cancer and has demonstrated substantial improvements in symptom control and overall survival compared with standard-of-care treatment. Prostate cancer is considered an immunologically cold tumour, so limited studies investigating the treatment-induced effects on the immune response have been completed. However, emerging data support the idea that radiotherapy induces an immune response in prostate cancer, but whether the response is an antitumour or pro-tumour response is dependent on the radiotherapy regime and is also cell-line dependent. In vitro data demonstrate that single-dose radiotherapy regimes induce a greater immune-suppressive profile than fractionated regimes; less is known about the immune response induced by molecular radiotherapy agents, but evidence suggests that these agents might induce an immune-suppressive systemic immune response, indicated by increased expression of inhibitory checkpoint molecules such as programmed cell death 1 ligand 1 and 2, and that these changes could be associated with clinical response. Different radiotherapy modalities can induce distinct immune profiles, which can either activate or suppress immune-mediated tumour killing and the current preclinical models used for prostate cancer research are not yet optimal for studying the complexity of the radiotherapy-induced immune response. This Review focusses on what is known about the interactions between conventional radiotherapy and the immune system. The authors discuss how this knowledge can be applied to investigate gaps regarding the immune interactions of molecular radiotherapies.","PeriodicalId":19088,"journal":{"name":"Nature Reviews Urology","volume":"21 11","pages":"651-661"},"PeriodicalIF":12.1,"publicationDate":"2024-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142081118","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Field effect and forerunner genes drive bladder cancer initiation 场效应和先驱基因驱动膀胱癌的发生

IF 12.1 1区医学

Nature Reviews Urology Pub Date : 2024-08-12 DOI: 10.1038/s41585-024-00929-0

Maria Chiara Masone

引用次数: 0

AI for drug discovery 人工智能促进药物研发

IF 12.1 1区医学

Nature Reviews Urology Pub Date : 2024-08-09 DOI: 10.1038/s41585-024-00931-6

Louise Lloyd

引用次数: 0

Utility of PSA screening in transgender women receiving oestrogens 接受雌激素治疗的变性女性接受 PSA 筛查的效用